

Unless otherwise defined herein, capitalized terms in this announcement shall have the same meanings as those defined in the prospectus dated September 23, 2022 (the “**Prospectus**”) issued by AIM Vaccine Co., Ltd. (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The H Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or any state securities laws of the United States. The securities may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in transactions in reliance on Regulation S under the U.S. Securities Act.



AIM Vaccine Co., Ltd.

艾美疫苗股份有限公司

(a joint stock company incorporated in the People’s Republic of China with limited liability)

(Stock Code: 06660)

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Joint Global Coordinators, on behalf of the International Underwriters, on October 28, 2022 in respect of an aggregate of 1,348,600 H Shares (the “**Over-allotment Shares**”), representing approximately 13.9% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price of HK\$16.16 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%).

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on October 28, 2022, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

Further information of stabilizing actions undertaken by Goldman Sachs (Asia) L.L.C., as stabilization manager (the “**Stabilization Manager**”) during the stabilization period is set out in this announcement.

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been partially exercised by the Joint Global Coordinators, on behalf of the International Underwriters, on October 28, 2022 in respect of an aggregate of 1,348,600 H Shares, representing approximately 13.9% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option.

The Over-allotment Shares will be issued and allotted by the Company at the Offer Price of HK\$16.16 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%). The Over-allotment Shares will be used to cover the over-allocation in the International Offering.

Approval of Listing

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in such Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on November 2, 2022.

Share Capital upon the Completion of the Partial Exercise of the Over-allotment Option

The shareholding structure of the Company immediately before and immediately after the completion of the partial exercise of the Over-allotment Option is as follows:

| Description of Shares | Immediately before the completion of the partial exercise of the Over-allotment Option | | Immediately after the completion of the partial exercise of the Over-allotment Option | |
|---|--|--|---|--|
| | <i>Number of Shares</i> | <i>Approximate % of total issued share capital</i> | <i>Number of Shares</i> | <i>Approximate % of total issued share capital</i> |
| Domestic Shares | 718,888,888 | 59.43% | 718,888,888 | 59.36% |
| H Shares converted from Domestic Shares | 481,111,111 | 39.77% | 481,111,111 | 39.73% |
| H Shares issued pursuant to the Global Offering | 9,714,000 | 0.80% | 11,062,600 | 0.91% |
| Total | <u>1,209,713,999</u> | <u>100%</u> | <u>1,211,062,599</u> | <u>100%</u> |

Use of Proceeds

The additional net proceeds of approximately HK\$21.6 million to be received by the Company from the issue and allotment of the Over-allotment Shares, after deduction of underwriting commissions and estimated expenses payable by the Company in connection with the exercise of the Over-allotment Option, will be used by the Company for the purposes as set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on Friday, October 28, 2022, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The stabilizing actions undertaken by the Stabilization Manager, or any person acting for it, during the stabilization period were:

- (1) the over-allocation of an aggregate of 1,457,000 H Shares in the International Offering, representing approximately 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
- (2) purchases of an aggregate of 307,800 H Shares in the price range of HK\$15.00 to HK\$16.16 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period, representing approximately 3.2% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option. The last purchase made by the Stabilization Manager or any person acting for it on the market during the stabilization period was on October 6, 2022 at the price of HK\$16.10 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%);
- (3) sale of an aggregate of 199,400 H Shares in the price range of HK\$19.00 to HK\$21.95 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period, representing approximately 2.1% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option. The last sale made by the Stabilization Manager or any person acting for it on the market during the course of the stabilization period was on October 28, 2022 at the price of HK\$21.85 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027%, FRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%); and
- (4) the partial exercise of the Over-allotment Option by the Joint Global Coordinators, on behalf of the International Underwriters, on October 28, 2022 in respect of an aggregate of 1,348,600 H Shares, representing approximately 13.9% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price to cover the over-allocation in the International Offering.

PUBLIC FLOAT

Immediately after the completion of the issue of H Shares pursuant to the Over-allotment Option, the Company will continue to comply with the public float requirements under Rule 8.08(1) of the Listing Rules.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, October 28, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA as Executive Directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO, Ms. Aijun WANG as Non-executive Directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as Independent Non-executive Directors.